Evidence map›Paper›PMID 38411874›Full record

ArticleEndocrine2024

Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study.

Takuya Mikoshiba, Mariko Sekimizu, Takeyuki Kono, Ryoto Nagai, Taiji Kawasaki, Yoichiro Sato, Fumihiro Ito, Nana Nakahara, Seiji Shigetomi, Hiroyuki Ozawa

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Guideline
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Takuya MikoshibaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan. takmikoshiba@yahoo.co.jp.ORCID 0000-0001-6206-6214
Mariko SekimizuDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Takeyuki KonoDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Ryoto NagaiDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Taiji KawasakiDepartment of Otolaryngology, Head and Neck Surgery, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
Yoichiro SatoDepartment of Otolaryngology, Saiseikai Utsunomiya Hospital, Tochigi, Japan.
Fumihiro ItoDepartment of Otolaryngology, National Tokyo Medical Center, Tokyo, Japan.
Nana NakaharaDepartment of Otolaryngology, Saitama City Hospital, Saitama, Japan.
Seiji ShigetomiDepartment of Otolaryngology, Head and Neck Surgery, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan.
Hiroyuki OzawaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Keio University · JPKawasaki Municipal Hospital · JPSaiseikai Utsunomiya hospital · JPSaitama Municipal Hospital · JPShizuoka Red Cross Hospital · JPTokyo Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLenvatinib achieves favorable therapeutic outcomes for patients with radioactive iodine therapy refractory differentiated thyroid cancer (DTC); however, its use is associated with a high incidence of adverse events. To avoid severe adverse events, planned drug holidays (PDH) have been proposed. This study aimed to evaluate treatment effects, identify prognostic factors, and investigate the usefulness of PDH in patients with unresectable DTC who received lenvatinib across the multi-institutions.

methodsFifty-one patients with unresectable DTC treated with lenvatinib were evaluated retrospectively. Overall survival (OS) and progression-free survival (PFS) were calculated, and prognostic factors were assessed. OS, PFS, and time to treatment failure (TTF) were compared between patients with and without PDH. Lenvatinib administration schedule was evaluated in PDH.

resultsThe 3-year OS and PFS rate were 53.5% and 42.1%, respectively. Multivariate analysis revealed that presence of maximum size of lung metastasis ≥10 mm was independent prognostic factor for poorer OS and PFS, and histology other than papillary thyroid carcinoma was the independent prognostic factor for poorer PFS. Twenty-five patients (49%) treated with PDH. There were significant differences in OS, PFS, and TTF between patients with and without PDH. Various schedules were used in PDH. Eight (32%) patients required switch to the different administration schedule.

conclusionOur results suggest that PDHs may extend OS, PFS, and TTF. In patients with PDH, various schedules used for lenvatinib administration highlight the difficulty in determining a uniform administration schedule. Therefore, it is crucial to consider the optimal lenvatinib administration schedule on a case-by-case basis.

Indexed as

Antineoplastic AgentsPhenylurea CompoundsQuinolinesThyroid NeoplasmsAdultAgedDrug Administration ScheduleFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeAntineoplastic AgentslenvatinibPhenylurea CompoundsQuinolinesAdverse eventsLenvatinibPlanned drug holidaysPrognosisThyroid cancer

Identifiers

PMID38411874
OpenAlexW4392200239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.